Sun Xiao-Hong, Wan Shun, Li Zi-Jian
The First Clinical Medical College of Lanzhou University；Lanzhou 730000,Gansu Province, China.
The Second Clinical Medical College of Lanzhou University；Lanzhou 730000,Gansu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Dec;29(6):1987-1990. doi: 10.19746/j.cnki.issn.1009-2137.2021.06.052.
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease. HCV is not only related to hepatic malignancies but may also promote lymphoid neoplasms. Currently, research has confirmed HCV-related lymphoma, including marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and Burkitt lymphoma (BL). Many types of research have shown that antiviral therapy can improve or even remission several HCV-related lymphomas. The direct-acting antiviral agents (DAAs) (such as NS5A protease inhibitors, NS4/4A protease inhibitors and viral polymerase inhibitors) have shown clinical advantages of high efficacy and low side effects for both virus elimination and tumor regression in several HCV-related lymphomas, which may make the selected HCV-related lymphoma patients treated without chemotherapy. In this review the research progress and development direction of antiviral therapy in treating HCV-related lymphoma has summarized briefly.
丙型肝炎病毒（HCV）是慢性肝病的主要病因之一。HCV不仅与肝脏恶性肿瘤有关，还可能促进淋巴肿瘤的发生。目前，研究已证实HCV相关淋巴瘤，包括边缘区淋巴瘤（MZL）、淋巴浆细胞淋巴瘤（LPL）、滤泡性淋巴瘤（FL）、弥漫性大B细胞淋巴瘤（DLBCL）和伯基特淋巴瘤（BL）。许多类型的研究表明，抗病毒治疗可以改善甚至缓解几种HCV相关淋巴瘤。直接作用抗病毒药物（DAAs）（如NS5A蛋白酶抑制剂、NS4/4A蛋白酶抑制剂和病毒聚合酶抑制剂）在几种HCV相关淋巴瘤的病毒清除和肿瘤消退方面均显示出高效和低副作用的临床优势，这可能使选定的HCV相关淋巴瘤患者无需化疗即可接受治疗。在这篇综述中，简要总结了抗病毒治疗在治疗HCV相关淋巴瘤方面的研究进展和发展方向。
